4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Replimune Group, Inc. (REPL) operates in the Biotechnology industry and is headquartered in Woburn, United States with about 465 employees. Its market capitalization is roughly $933 million. In the fiscal year ended 2026-03-31, REPL reported $0M in revenue and ($314M) in net income.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($318M) | ($260M) | ($233M) | ($174M) | — |
| Net Income | ($314M) | ($247M) | ($216M) | ($174M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($73M) | ($72M) | ($84M) | ($90M) | ($79M) | — |
| Net Income | ($73M) | ($71M) | ($83M) | ($87M) | ($74M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $332M | $551M | $488M | $647M | — |
| Total Liabilities | $166M | $136M | $113M | $91M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive REPL viewer.
About TickerBase · Data methodology & sources